Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
US10966945B2 · kind B2 · utility
0Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2011 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Jun 19, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P33/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.